KR20070076800A - A preparation method of nordihydroguaiaretic acid and its analogues - Google Patents

A preparation method of nordihydroguaiaretic acid and its analogues Download PDF

Info

Publication number
KR20070076800A
KR20070076800A KR1020060006119A KR20060006119A KR20070076800A KR 20070076800 A KR20070076800 A KR 20070076800A KR 1020060006119 A KR1020060006119 A KR 1020060006119A KR 20060006119 A KR20060006119 A KR 20060006119A KR 20070076800 A KR20070076800 A KR 20070076800A
Authority
KR
South Korea
Prior art keywords
isomers
meso
isomer
ndga
reaction
Prior art date
Application number
KR1020060006119A
Other languages
Korean (ko)
Other versions
KR100783626B1 (en
Inventor
장영동
이승호
손종근
Original Assignee
영남대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 영남대학교 산학협력단 filed Critical 영남대학교 산학협력단
Priority to KR1020060006119A priority Critical patent/KR100783626B1/en
Publication of KR20070076800A publication Critical patent/KR20070076800A/en
Application granted granted Critical
Publication of KR100783626B1 publication Critical patent/KR100783626B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/11Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms
    • C07C37/20Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by reactions increasing the number of carbon atoms using aldehydes or ketones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/68Purification; separation; Use of additives, e.g. for stabilisation
    • C07C37/88Use of additives, e.g. for stabilisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01Preparation of ethers
    • C07C41/32Preparation of ethers by isomerisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/02Ethers
    • C07C43/20Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/205Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring
    • C07C43/2055Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring the aromatic ring being a non-condensed ring containing more than one ether bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A method for preparing nordihydroguaiaretic acid and derivatives thereof is provided to mass-produce nordihydroguaiaretic acid and derivatives thereof having an antioxidative activity in a simple manner. The novel method for preparing a derivative of nordihydroguaiaretic acid represented by the following chemical formula 1 in a high yield comprises the steps of: reacting a Grignard reagent prepared from the following bromine compound(2) with a ketone material(3) to prepare an alcohol material(4); dehydrating the alcohol material(4) with a dehydrating agent to obtain a (Z) isomer(5Z) and an (E) isomer of a butene material, respectively; hydrogenating the respective (Z) and (E) isomers in the presence of a catalyst to obtain a meso isomer(6-meso) and racemate((±)-6) of a butane material, respectively; and demethylating the meso isomer(6-meso) and racemate((±)-6) of the butane material.

Description

항산화 활성을 갖는 NDGA 및 그 유도체 합성법{A preparation method of nordihydroguaiaretic acid and its analogues}A preparation method of nordihydroguaiaretic acid and its analogues

본 발명은 항산화 활성을 갖는 NDGA 및 그 유도체 화합물을 간단한 방법으로 제조 가능한 신규 제조방법에 관한 것이다. The present invention relates to a novel process for producing NDGA and its derivative compounds having antioxidant activity by a simple method.

항산화 활성이란 생체 내 활성산소의 생성을 방지하고 세포에 회복 불가능한 손상을 야기하는 산화현상을 방지하는 활성을 말한다. 안정한 상태의 산소 (triplet oxygen)는 효소계, 환원대사, 화학약품, 공해물질, 광화학 반응과 같은 환경적 및 생화학적 요인 등에 의해 수퍼옥사이드 라디칼, 하이드록시 라디칼, 과산화수소와 같은 반응성이 큰 활성산소(Reactive Oxygen Species: ROS)로 전환되어 세포구성성분을 비가역적으로 파괴한다. 이들 활성산소의 작용은 체내 방어기구인 수퍼옥사이드디스뮤타제(SOD), 카탈라아제(catalase), 퍼옥시다아제(peroxidase) 등의 항산화성 효소 및 비타민 C(vitamin C), 비타민 E(vitamin E), 글루타티온 (glutathione) 등의 항산화 물질의 작용에 의하여 최소화 될 수 있다. 그러나, 이러한 생체 방어력에 이상이 생기거나 과도한 활성산소에 노출될 경우, 이 균형이 깨어져서 활성산소가 지질, 단백질, DNA 등을 비가역적으로 파괴하게 된다. 그 결 과, 노화(aging), 암(cancer), 복합성 동맥경화(multiple atherosclerosis), 관절염 및 파킨슨병(Parkinson's disease)과 같은 각종 질병이 유발된다.Antioxidant activity refers to an activity that prevents the production of free radicals in vivo and prevents oxidative phenomena that cause irreparable damage to cells. The stable oxygen (triplet oxygen) is a highly reactive reactive oxygen such as superoxide radicals, hydroxy radicals, hydrogen peroxide due to enzymatic system, reducing metabolism, chemicals, pollutants, and photochemical reactions Oxygen Species (ROS), which irreversibly destroy cellular components. The action of these free radicals is antioxidant enzymes such as superoxide dismutase (SOD), catalase, peroxidase, and vitamin C, vitamin E, glutathione ( It can be minimized by the action of antioxidants such as glutathione). However, if the biological defenses are abnormal or exposed to excessive free radicals, the balance is broken and the free radicals irreversibly destroy lipids, proteins, DNA, and the like. As a result, various diseases such as aging, cancer, multiple atherosclerosis, arthritis and Parkinson's disease are caused.

지금까지 개발된 합성 항산화제로는, BHA(butylated hydroxy anisole), BHT (butylated hydroxytoluene), NDGA(nordihydroguaiaretic acid) 등이 있으며, 천연 항산화제로는 수퍼옥사이드 디스뮤타제, 퍼옥시다아제, 카탈라아제, 글루타티온 퍼옥시다아제 등의 항산화효소와 토코페롤(비타민 E), 비타민 C(ascorbic acid), 카로테노이드, 글루타티온 등의 비효소적 항산화물질 등이 있다.Synthetic antioxidants developed so far include butylated hydroxy anisole (BHA), butylated hydroxytoluene (BHT), nordihydroguaiaretic acid (NDGA), and natural antioxidants such as superoxide dismutase, peroxidase, catalase, glutathione peroxidase and the like. And antioxidant enzymes such as tocopherol (vitamin E), vitamin C (ascorbic acid), carotenoids and glutathione.

자연계에 널리 분포되어 있으며 가장 대표적인 항산화제로 간주되고 있는 페놀성 화합물은 고리구조에 치환 가능한 하이드록실(OH)기를 한 개 이상 가진 이차대사산물이다. 이 화합물은 포유동물 효소계의 다양함을 위한 저해제와 촉진제로서, 그리고 산소라디칼의 소거제와 금속 킬레이터로 작용한다. 이러한 항산화 활성은 컨쥬게이션된 환과 하이드록실기에 연관되어 있으므로 대부분의 페놀성 화합물이 항산화 활성을 가지는 점은 놀라운 일이 아니라 할 수 있다(Sanchez-Moreno C et al., Food Res. Int . 32, pp 407~412, 1999; Decker EA., Nutr . Rev. 53, pp 49~58, 1995).Phenolic compounds, widely distributed in nature and considered to be the most representative antioxidants, are secondary metabolites with one or more hydroxyl (OH) groups in the ring structure. These compounds act as inhibitors and promoters for a variety of mammalian enzyme systems and as scavengers and metal chelators of oxygen radicals. Since this antioxidant activity is related to conjugated rings and hydroxyl groups, it is not surprising that most phenolic compounds have antioxidant activity (Sanchez-Moreno C et al., Food Res. Int . 32 , pp 407-412 , 1999; Decker EA., Nutr . Rev. 53 , pp 49-58 , 1995).

노르디하이드로갈리아레틱산(NDGA, 1aa)는 라레아 디베러케이트(Larrea divaricata Cav. )와 같은 북아메리카산 작은떡갈나무덤불의 수지를 함유한 삼출액으로부터 분리시킨 무독성 페놀성 리그난(phenolic lignan)이다. 더하여, 식품의 산화방지제로써(Lundberg, W. O. et al., Oil & Soap, 21, pp 33-35, 1944) 사용되며, NDGA는 리폭시게나아제(lipoxygenase)(Skaltsa, H. et al., J. Biol . Pharm . Bull. 23, p 47, 2000), 염증유도시스템(Steele, V. E. et al., J. Expert Opin . Investig. Drugs, 9, p 2121, 2000; Whitman, S. et al., J. Med . Chem . 45, p 2659, 2002), 단순포진(herpes simples)(Chen, H. et al., J. Med . Chem . 41, p 3001, 1998), HIV(Hwu, J. R. et al., J. Med . Chem. 41, p 2994, 1998) 및 유두종 바이러스(human papillomavirus)(Craigo, J. et al., Antivir . Res. 47, p 19, 2000) 뿐만 아니라 고혈당 활성(hyperglycemic activity)(Reed, M. J. et al., Diabetologia, 42, p 102, 1999)의 활성을 억제하는 것을 포함하는 약학 조성물이므로 계속적으로 관심이 증가되어 오고 있다. NDGA 유도체인 테트라-O-메틸-NDGA (tetra-O-methyl-NDGA)(1ea)는 종양제거효과(tumoricidal activity)를 보였으며(미국특허출원 제 6417234호; Heller, J. D. et al., Cancer Res. 54, p 1991s, 1994; Heller, J. D. et al., Cancer Res. 61, p 5499, 2001), 화합물 (1ca)(1eb)(machillin A)는 멜라닌 합성에 강한 억제활성을 보였다(Li, G. et al., Biol. Pharm . Bull. 26, p 1039, 2003).Norddihydrogalleatic acid (NDGA, 1aa) is a non-toxic phenolic lignan isolated from effluents containing resins of North American oak bushes, such as Larrea divaricata Cav. In addition, it is used as an antioxidant in food (Lundberg, WO et al., Oil & Soap , 21 , pp 33-35, 1944), and NDGA is a lipoxygenase (Skaltsa, H. et al., J. Biol . Pharm . Bull. 23 , p 47, 2000), inflammatory induction system (Steele, VE et al., J. Expert Opin . Investig.Drugs, 9 , p 2121, 2000; Whitman, S. et al., J . Med. Chem. 45, p 2659, 2002), HSV (herpes simples) (Chen, H. et al., J. Med. Chem. 41, p 3001, 1998), HIV (Hwu, JR et al. , J. Med . Chem . 41 , p 2994, 1998) and human papillomavirus (Craigo, J. et al., Antivir . Res . 47 , p 19, 2000), as well as hyperglycemic activity ( Reed, MJ et al., Diabetologia, 42 , p 102, 1999) has been of increasing interest as it is a pharmaceutical composition comprising inhibiting the activity of. Tetra-O-methyl-NDGA (1ea), an NDGA derivative, showed tumoricidal activity (US Patent Application No. 6417234; Heller, JD et al., Cancer Res) 54 , p 1991s, 1994; Heller, JD et al., Cancer Res . 61 , p 5499, 2001), compounds (1ca) and (1eb) (machillin A) showed strong inhibitory activity on melanin synthesis (Li, G. et al., Biol. Pharm . Bull . 26 , p 1039, 2003).

리그난의 제조를 위한 효과적인 합성법 개발을 위한 노력은 수 십년 동안 계속되었다. 1aa의 첫 합성은 천연물로부터 분리되기 수 십년 전인 1918년에 수소화된 (-)-갈리아레틱 산(guaiaretic acid)의 디메틸에테르(dimethyl ether)(1ba)의 탈메틸화(dimethylation)의 방법으로 수행되었다(Schroter, G. et al., Ber . 51, p 1587, 1918). 이후, 천연물로부터 분리된 1aa 의 현재의 구조는 합성을 통해 확인되었다(Haworth, R. D. et al., J. Chem . Soc . p 1423, 1934; Haworth, R. D. et al., J. Chem . Soc. p 120, 1935; Perry, C. W. et al., J. Org . Chem . 37, p 4371, 1972). 보다 더 체계적인 합성은, 1-피페로닐-1-브로모에탄과 그것으로부터 유래한 그리그나드 시약(Grignard reagent)의 반응을 주반응(key reaction)으로 하는 합성방법으로 1947년에 발표되었다(Liebermann, S. V. et al., J. Am. Chem . Soc. 69, p 1540, 1947; Sakakibara, Y., Nippon Kagaku Zasshi , 73, p 235, 1952; Blears, J. G. et al., J. Chem . Soc ., Abstracts 1958, 1985). 이와 같이 이 방법은 수년 동안 개량되어 왔으나, 수득률이나 원하는 입체이성체에 대한 선택성을 증가시키는 데에는 실패한바 있다(Hearon, W. M. et al., Chem . Rev. 55, p 957, 1955). 치환된 페닐아세톤의 Ti-유도된 카보닐 커플링 반응은 예상했던 맥머리-형(McMurry type)부텐 대신에 1,4-이치환-부탄-2,3-디올(1,4-disubstitued-butane-2,3-diols)을 제조한바 있다(Gezginci, M. et al., Tetrahderon Letters, 42, p 6083, 2001). 베타-케토 에스테르의 산화적인 커플링 방법(Gu, W. X. et al., Chin. Chem . Letters, 11, p 15, 2000), 디에틸 숙시네이트(diethyl succinate)와 피페로날을 이중 축합한 후 두 단계의 환원단계를 거치는 방법(Xia, Y. M. et al., Chin. Chem . Letters, 14, p 359, 2003), 금속-포스핀 복합체에 의하여 촉매되는 할로티오펜의 그리그나드 커플링 반응과 이에 따른 촉매환원 방법 (Minato, A. et al., Tetrahderon Letters, 21, p 4017, 1980)등이 수행되었다. 이러한 방법들은 입체이성체에 대한 선택성과 수득률을 어느 정도 향상시켰으나, 시약의 원가, 반응의 저수율, 긴 반응단계의 필요 등의 단점이 있을 뿐만 아니라 비대칭적으로 치환된 NDGA만을 얻는 데에는 한계를 갖고있었다. Efforts to develop effective synthesis for the production of lignans have continued for decades. The first synthesis of 1aa was carried out by the demethylation of dimethyl ether (1ba) of hydrogenated (-)-guaiaretic acid in 1918, decades before it was separated from natural products. Schroter, G. et al., Ber . 51 , p 1587, 1918). Later, the current structure of 1aa isolated from natural products was confirmed by synthesis (Haworth, RD et al., J. Chem . Soc . P 1423, 1934; Haworth, RD et al., J. Chem . Soc . P. 120, 1935; Perry, CW et al., J. Org . Chem . 37 , p 4371, 1972). A more systematic synthesis was published in 1947 as a synthesis method whereby the reaction of 1-piperonyl-1-bromoethane and the Grignard reagent derived therefrom is the key reaction ( Liebermann, SV et al., J. Am. Chem . Soc . 69 , p 1540, 1947; Sakakibara, Y., Nippon Kagaku Zasshi , 73 , p 235, 1952; Blears, JG et al., J. Chem . Soc . , Abstracts 1958, 1985). As such, this method has been improved for many years, but failed to increase the yield or selectivity for the desired stereoisomer (Hearon, WM et al., Chem . Rev. 55 , p 957, 1955). The Ti-derived carbonyl coupling reaction of substituted phenylacetones was performed using 1,4-disubstituted-butane-2,3-diol instead of the expected McMurry type butene. 2,3-diols) (Gezginci, M. et al., Tetrahderon Letters, 42 , p 6083, 2001). Oxidative coupling method of beta-keto esters (Gu, WX et al., Chin. Chem . Letters, 11 , p 15, 2000), after double condensation of diethyl succinate and piperonal (Xia, YM et al., Chin. Chem . Letters, 14 , p 359, 2003), the Grignard coupling reaction of halothiophenes catalyzed by metal-phosphine complexes Catalytic reduction method according to (Minato, A. et al., Tetrahderon Letters , 21 , p 4017, 1980) and the like. These methods have some improvement in selectivity and yield for stereoisomers, but also have disadvantages such as the cost of reagents, low yield of reactions, the need for long reaction steps, and limitations in obtaining only asymmetrically substituted NDGAs.

따라서, 이에 본 발명자들은 항산화 활성을 갖는 NDGA 및 그 유도체화합물을 간단하게 생산할 수 있으며 대량으로 생산이 가능하여 비대칭 NDGA의 제조가 가능한 새로운 제조방법을 개발한바, 본 발명을 완성하였다.Therefore, the present inventors have developed a novel manufacturing method that can easily produce NDGA and its derivative compounds having antioxidant activity and can be produced in large quantities, thus making asymmetric NDGA, and thus, the present invention has been completed.

본 발명의 목적은 항산화 활성을 갖는 NDGA 및 그 유도체 화합물을 간단하게 생산할 수 있으며 대량으로 생산 가능한 신규 제조방법을 제공하는 것이다. It is an object of the present invention to provide a novel production method which can produce NDGA and its derivative compounds having antioxidant activity simply and in large quantities.

상기 목적을 달성하기 위하여, 본 발명은 생물학적으로 중요한 천연물질인 NDGA 화합물(1) 뿐만 아니라 그 유도체의 제조방법을 연구함으로서, NDGA 및 이의 중간체인 1,4-디(치환된-페닐)-2,3-디메틸부탄-2-올과 관련된 리그난의 신규 제조방법을 제공한다.In order to achieve the above object, the present invention has studied NDGA compound (1) , which is a biologically important natural substance, as well as a method for preparing a derivative thereof, thereby providing NDGA and its intermediate 1,4-di (substituted-phenyl) -2. A novel process for preparing lignans associated with, 3-dimethylbutan-2-ol is provided.

따라서, 본 발명은 하기 브롬체 화합물(2)을 그리그나드 시약으로 변환시킨 후 케톤체(3)와 반응시켜 알콜체(4)를 제조하는 제 1단계; 상기 알콜체(4)를 탈수제 존재하에서 탈수반응시켜 부텐체의 (Z)이성체 (5-Z) 및 (E)이성체 (5-E)를 얻고 분리하는 제 2단계; 상기 2단계의 각각의 부텐체의 (Z) 및 (E) 이성체들을 촉매 존재하에 수소화 반응시켜 부탄체의 메조(meso)-이성체 (6- meso ) 및 라세믹(racemic)-이성체 ((±)-6)을 각각 얻는 제 3단계; 상기 단계의 부탄체의 메조 및 라세믹 이성체들을 탈메틸화 반응을 시키는 제4단계 공정을 포함하는 일반식 (1)의 NDGA 유도체를 고수율로 수득하는 신규 제조방법을 제공한다. Accordingly, the present invention provides the first step of converting the following bromine compound (2) into a Grignard reagent and then reacting with the ketone body (3) to produce an alcohol (4) ; Dehydrating the alcohol (4) in the presence of a dehydrating agent to obtain (Z) isomers (5-Z) and (E) isomers (5-E) of butenes; The (Z) and (E) isomers of each of the two butenes in the above two steps are hydrogenated in the presence of a catalyst to give meso -isomers (6- meso ) and racemic-isomers ((±) of butane . -6) third step of obtaining each; It provides a novel process for obtaining a high yield of the NDGA derivative of the general formula (1) comprising a fourth step of demethylating the meso and racemic isomers of the butane body of the above step.

Figure 112006004305024-PAT00001
Figure 112006004305024-PAT00001

상기 식에서 R1 내지 R4 기는 각각 독립적으로 수소 원자, 또는 메틸기, 에틸기 등의 저급 알킬기이며 서로 같거나 다를 수 있다. In the above formula, R 1 to R 4 groups are each independently a hydrogen atom or a lower alkyl group such as a methyl group or an ethyl group and may be the same as or different from each other.

Figure 112006004305024-PAT00002
Figure 112006004305024-PAT00002

Figure 112006004305024-PAT00003
Figure 112006004305024-PAT00003

Figure 112006004305024-PAT00004
Figure 112006004305024-PAT00004

Figure 112006004305024-PAT00005
Figure 112006004305024-PAT00005

Figure 112006004305024-PAT00006
Figure 112006004305024-PAT00006

Figure 112006004305024-PAT00007
Figure 112006004305024-PAT00007

Figure 112006004305024-PAT00008
Figure 112006004305024-PAT00008

상기 식에서 X는 메틸렌기 또는 개환시 수소 원자 또는 메틸기, 에틸기 등의 저급알킬기이다. In the above formula, X is a methylene group or a lower alkyl group such as a hydrogen atom or a methyl group or an ethyl group at the time of ring opening.

상기 제조공정의 제 1단계에서는 반응을 촉진시키기 위하여, 마그네슘 편(turning) 이외에 요오드 결정을 추가로 가할 수 있으며, 상기 2단계의 탈수 반응에서 사용가능한 탈수제로는 황산, 포스포릴 클로라이드(POCl3) 등을 사용할 수 있으나, 황산을 사용함이 바람직하며, 상기 3단계의 수소화 반응 단계에는 촉매로서 그 종류와 사용량에는 제한을 두지는 않으나 PtO2를 사용함이 바람직하며, 상기 4단계에서 탈메틸화 반응에 사용하는 탈메틸화 시약으로는 삼불화붕소 등이 바람직하다.In the first step of the manufacturing process, in order to promote the reaction, iodine crystals may be additionally added in addition to the magnesium turning, and the dehydrating agent usable in the second dehydration reaction may be sulfuric acid, phosphoryl chloride (POCl 3 ). Although it may be used, it is preferable to use sulfuric acid, and the hydrogenation reaction step of the three steps is not limited to the type and the amount used as a catalyst, but it is preferable to use PtO 2 , used in the demethylation reaction in the fourth step As the demethylation reagent, boron trifluoride and the like are preferable.

본 발명의 목적은 항산화제로서 활성을 갖는 NDGA 및 그 유도체의 제조방법을 제공하는 것으로, 하기의 반응식들에 도시된 방법에 의해 화학적으로 합성될 수 있지만, 이들 예로만 한정되는 것은 아니다. An object of the present invention is to provide a method for preparing NDGA and its derivatives, which are active as antioxidants, which can be chemically synthesized by the methods shown in the following schemes, but is not limited thereto.

하기의 반응식들은 본 발명의 화합물들의 제조방법을 제조 단계별로 나타내는 것으로 본 발명의 화합물은 반응식의 합성과정에서 사용되는 시약, 용매 및 반응 순서를 바꾸는 등의 작은 변경으로 제조될 수 있다. The following schemes represent the preparation steps of the compounds of the present invention in stages of preparation. The compounds of the present invention may be prepared with minor modifications, such as changing the reagents, solvents, and reaction sequences used in the synthesis of the schemes.

먼저 본 발명의 반응 단계는 하기한 반응식에 기재된 도식에 의하여 설명된다.First, the reaction step of the present invention is illustrated by the scheme described in the following scheme.

Figure 112006004305024-PAT00009
Figure 112006004305024-PAT00010
Figure 112006004305024-PAT00009
Figure 112006004305024-PAT00010

먼저, 상기 제 1단계에서 브롬화 화합물 (2)을 마그네슘 처리하여 그리그나드 시약(Grignard reagents)으로 만들고 이를 케톤체 (3)를 반응시켜 알콜체 (4)를 얻을 수 있다. 상기 단계에서 얻은 알콜체 (4)는 에리스로(erythro-)와 트레오(threo-)이성질체의 혼합물로써 두 가지 입체이성질체 형태로 존재한다. 그러나 본 발명에서는 상기 이성질체의 분리를 시도하지 않고 그 대신 혼합물을 즉시 다음 단계로 수행한다. First, in the first step, the brominated compound (2) may be treated with magnesium to form Grignard reagents, and the ketone body (3) may be reacted to obtain an alcohol (4) . Alcohol product (4) obtained in the above step are present as a mixture of erythro (erythro-) and Treo (threo-) isomer in two stereoisomeric forms. In the present invention, however, the separation of the isomers is not attempted and instead the mixture is carried out immediately to the next step.

Figure 112006004305024-PAT00011
Figure 112006004305024-PAT00011

상기 알콜체 (4)를 농축 황산 등과 같은 탈수제하에서 탈수반응시켜 부텐체의 두 위치 이성체(regioisomer) (Z)이성체 (5-Z) 및 (E)이성체 (5-E)를 약 70%의 수율로 얻을 수 있다. 이 때 (5a-Z)(5a-E)의 비율은 3.8:6.2로, 5b의 경우는 3.5:6.5의 비율로 각각 나타났다. 두 위치 이성체는 실온에서 Z-이성질체가 유상(oil)인 것에 반해 E-이성질체는 결정이므로 쉽게 분리되며, (Z)이성체 (5-Z) 및 (E)이성체 (5-E)의 구조는 1H NMR 결과와 수소화 반응 생성물의 문헌치의 값과 일치하는 지를 비교함으로써 확인하는 과정을 수행하였다. The alcohol (4) was dehydrated under a dehydrating agent such as concentrated sulfuric acid to yield about 70% of the bipositional regioisomer (Z) isomer (5-Z) and (E) isomer (5-E) of the butene body. Can be obtained. At this time , the ratio of (5a-Z) and (5a-E) was 3.8: 6.2, and in the case of 5b , the ratio was 3.5: 6.5. The two positional isomers are easily separated because the Z-isomer is oil at room temperature, whereas the E-isomer is a crystal, and the structure of the (Z) isomers (5-Z) and (E) isomers (5-E) is 1 Confirmation was carried out by comparing the H NMR results with the values of the literature values of the hydrogenation reaction product.

Figure 112006004305024-PAT00012
Figure 112006004305024-PAT00012

Figure 112006004305024-PAT00013
Figure 112006004305024-PAT00013

상기 단계에서 얻은 부텐체의 두 위치 이성체(regioisomer) (Z)이성체 (5-Z) 및 (E)이성체 (5-E)를 PtO2 등의 반응 촉매 하에서의 수소화 반응을 시킴으로써 (E)이성체 (5-E)로부터 부탄체의 메소 이성체 (6- meso )1db1 eb를 얻은 반면, (Z)이성체 (5-Z)로부터 라세믹 이성체 ((±)-6)1da 1 ea를 각각 85%이상의 고수율로 얻을 수 있다.The two-position regioisomer (Z) isomer (5-Z) and (E) isomer (5-E) of the butenes obtained in the above step are subjected to hydrogenation reaction under a reaction catalyst such as PtO 2 to give (E) isomer (5 ). -E) obtained 1db and 1 eb of the butane meso isomer (6- meso ) , whereas 1da and 1 ea of the racemic isomer ((±) -6) were obtained from the (Z) isomer (5-Z) , respectively. A high yield of more than 85% can be obtained.

다음 단계로서 상기 단계의 부탄체의 메소 및 라세믹 이성체들을 삼불화붕소(BBr3)와 같은 시약으로 탈메틸화 반응(demethylation)을 시켜 목적하는 NDGA (1aa)를 수율(75%)로 수득할 수 있다. As a next step, demethylation of the meso and racemic isomers of the butane in the above step with a reagent such as boron trifluoride (BBr 3 ) can be carried out to obtain the desired NDGA (1aa) in yield (75%). have.

추가적으로, 본 발명은 하기와 같은 반응식 4과 같은 공정에 통하여 NDGA 및 그 유도체를 제조가능하다. In addition, the present invention can be prepared NDGA and its derivatives by the same process as in Scheme 4.

Figure 112006004305024-PAT00014
Figure 112006004305024-PAT00015
Figure 112006004305024-PAT00014
Figure 112006004305024-PAT00015

Figure 112006004305024-PAT00016
Figure 112006004305024-PAT00016

본 발명에서 출발물질 화합물 (2a)(3b)은 공지 방법을 이용하여 제조가능하거나 상용으로 구입 가능한 3,4-치환된-1-아릴벤젠으로부터 합성이 가능하다. The starting compounds (2a) and (3b) in the present invention can be synthesized from 3,4-substituted-1-arylbenzenes which can be prepared using commercially known methods or commercially available.

상기 반응식과 같이 2a3b를 반응하여 82%의 수율로 카비놀(carbinol) 4c를 얻을 수 있다. 4c의 3단계 변환은 새로운 NDGA 유도체인 1fa 1 fb를 각각 54% 및 45%의 수율로 얻을 수 있다. Carbinol 4c can be obtained in a yield of 82% by reacting 2a and 3b as in the above scheme. Three-step transformation of 4c yields new NDGA derivatives 1fa and 1 fb with yields of 54% and 45%, respectively.

Figure 112006004305024-PAT00017
Figure 112006004305024-PAT00017

상기 단계에서 얻은 1fa에 파라티오크레솔을 반응시켜 7a를 합성하고, 2단계 변환을 거쳐 NDGA 유도체인 1ca를 제조할 수 있다. Parafacrecresol was reacted with 1fa obtained in the above step to synthesize 7a , and 1ca , an NDGA derivative, may be prepared through two-step conversion.

결론적으로, 본 발명의 NDGA 및 그 유도체의 제조를 위한 간단하고 효율적인 반응과정으로 브롬체 화합물로부터 제조한 그리그나드 시약과 출발물질로 손쉽게 제조할 수 있는 케톤을 반응시키는 과정, 탈수과정, 수소화과정을 주요과정으로 하며, 본 발명의 과정은 기존의 대칭 NDGA의 기존의 제조방법보다 우수할 뿐만 아니라 비대칭적으로 치환된 NDGA 유도체의 제조 방법으로도 유용하다. In conclusion, as a simple and efficient reaction process for the preparation of the NDGA and its derivatives of the present invention, a process for reacting a Grignard reagent prepared from a bromine compound with a ketone which can be easily prepared from a starting material, a dehydration process, and a hydrogenation process The process of the present invention is not only superior to the conventional method for preparing the symmetric NDGA, but also useful as a method for preparing the asymmetrically substituted NDGA derivative.

본 발명의 제조방법은 항산화제로서의 그 효능이 입증된 NDGA 및 그 유도체 화합물을 화학적으로 합성하게 됨으로서 보다 간단하고도 대량생산이 가능한 합성 방법을 제공하는 등의 산업적으로 유용한 제조방법을 제공한다. The production method of the present invention provides an industrially useful production method, such as providing a synthetic method that is simpler and mass-produced by chemically synthesizing NDGA and its derivative compounds, which have been proven effective as antioxidants.

이하, 본 발명은 하기 실시예에 의거하여 좀 더 상세하게 설명하고자 한다. 단, 하기 실시예는 본 발명을 예시하기 위한 것일 뿐, 본 발명의 범위가 이들 만으로 제한되는 것은 아니다. Hereinafter, the present invention will be described in more detail based on the following examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited thereto.

참고예Reference Example 1.  One. 사용기기Device used

본 실험에서 얻은 생성물의 구조 확인을 위해 사용된 기기는 하기와 같다.The instrument used to confirm the structure of the product obtained in this experiment is as follows.

융점(mp)는 피셔-존스 융점측정기(Fischer-Jones melting points apparatus)를 사용하였으며 보정은 하지 않았으며, 핵자기 공명 스펙트럼(1H NMR)은 250 MHz 또는 400 MHz (Bruker NMR spectrometer), 핵자기 공명 스펙트럼(13C NMR)은 100MHz (Bruker NMR spectrometer)로 내부표준물질(Internal standard)로 TMS (tetermethylsilane)을 사용하였다. IR은 퍼킨-엘머 분광기(Perkin-Elmer 1330 spectrophotometer)을 사용하여 측정하였다. 출발 물질은 2a, 2b, 3a3b가 공지의 방법에 따라 제조하여 사용하였다. 시약과 용매는 공업용 시약 등급을 이전의 정제 없이 사용하였다. 원소분석은 휴렛 펫커드(Hewlett-Packard)모델 185B 원소분석기로 수행되었다.Melting point (mp) was a Fischer-Jones melting point apparatus and was not calibrated. Nuclear magnetic resonance spectra ( 1 H NMR) were 250 MHz or 400 MHz (Bruker NMR spectrometer), nuclear magnetic The resonance spectrum ( 13 C NMR) was 100 MHz (Bruker NMR spectrometer) and TMS (tetermethylsilane) was used as an internal standard. IR was measured using a Perkin-Elmer 1330 spectrophotometer. Starting materials 2a, 2b, 3a and 3b were prepared and used according to a known method. Reagents and solvents used industrial reagent grades without prior purification. Elemental analysis was performed with a Hewlett-Packard model 185B elemental analyzer.

실시예Example 1. 1,4- 1.1,4- 비스Vis (3,4-(3,4- 메틸렌디옥시페닐Methylenedioxyphenyl )-2,3-디메틸-2-) -2,3-dimethyl-2- 부텐체Butene 이성체들((E)-5aa,(Z)-5ab)의 제조 Preparation of Isomers ((E) -5aa, (Z) -5ab)

건조 에테르 20ml에 마그네슘 터닝(Mg turning, 0.50g, 20.5mmol)을 가한 용액에 건조 에테르 50ml에 녹인 브로모-화합물(bromo-compound) 2a(5.00g, 20.5 mmol)를 주사기를 사용하여 격벽으로 천천히 가하였다. 반응의 초기화를 위해, 요오드(I2) 결정(20 mg)을 가하고, 생성된 혼합물은 1.5시간 동안 환류하였다. 반응 혼합물을 상온으로 냉각한 후, 건조 에테르 20ml에 녹인 3a(3.00g, 20.5 mmol)을 환류가 유지될 정도의 속도로 적가 하였다. 10분 동안의 적가가 끝나면, 30분 정도 추가적으로 가온한 다음 이어서 8시간 동안 실온에서 유지하였다. 아이스 베스(ice bath)에서 반응 혼합물을 냉각시킨 다음 쪼갠 얼음 10g을 가하였다. 그 뒤 2,5M의 황산(H2SO4) 50ml를 가한 다음 얻은 반응 혼합물을 에테르 50ml로 3회 추출하였다. 얻어진 유기층은 무수 황산마그네슘(MgSO4)으로 건조하였다. 용매를 증발시켜 유분물질(oily material)의 5.96g(85%)의 생성물을 얻었으며, 이는 1H NMR 확인시 다음 단계로 가기에 충분히 순수했다. 얻은 유상의 생성물 4a(3.42g, 0.01 mol)을 진한 황산 20 ml 녹인 뒤 혼합물은 2시간 동안 100℃에서 가열하였다. 반응 결과물은 에테르와 얼음의 혼합물(1:1, 100ml)로 옮겨 부었다. 얻어진 수층은 에테르 30ml로 2회 추출하였다. 유기층을 합친 다음 물로 씻긴 후, 무수황산마그네슘(MgSO4)으로 건조하였다. 용매를 증발시켜 유상의 생성물 2.36 g(73%)를 얻었고 이를 냉장고에서 결정화한 다음 에탄올에서 재결정하여 1.43g (44%)의 백색 침상의 1,4-비스(3,4-메틸렌디옥시페닐)-2,3-디메틸-2-부텐체 이성체((E)-5aa)를 얻고(1.43g, 44%), 이후 모액(Mother liquor)은 메틸렌클로라이드(CH2Cl2)로 용출하여 실리카겔 크로마토그래피법을 수행하여, 하기 물성치를 갖는 오일 형태의 부텐체 (Z)-5ab (0.89g, 수득율 27%)을 각각 수득하였다.Magnesium turning (0.50 g, 20.5 mmol) was added to 20 ml of dry ether and bromo-compound 2a (5.00 g, 20.5 mmol) dissolved in 50 ml of dry ether was slowly poured into the septum using a syringe. Was added. To initiate the reaction, iodine (I 2 ) crystals (20 mg) were added and the resulting mixture was refluxed for 1.5 hours. After the reaction mixture was cooled to room temperature, 3a (3.00 g, 20.5 mmol) dissolved in 20 ml of dry ether was added dropwise at a rate such that reflux was maintained. At the end of the 10 minute drop, it was further warmed for about 30 minutes and then kept at room temperature for 8 hours. The reaction mixture was cooled in an ice bath and then 10 g of crushed ice was added. Then, 50 ml of 2,5 M sulfuric acid (H 2 SO 4 ) was added, and the obtained reaction mixture was extracted three times with 50 ml of ether. The obtained organic layer was dried over anhydrous magnesium sulfate (MgSO 4 ). The solvent was evaporated to give 5.96 g (85%) of the product of the oily material, which was pure enough to go to the next step upon 1 H NMR confirmation. The obtained oily product 4a (3.42 g, 0.01 mol) was dissolved in 20 ml of concentrated sulfuric acid, and the mixture was heated at 100 ° C. for 2 hours. The reaction result was transferred to a mixture of ether and ice (1: 1, 100 ml). The obtained aqueous layer was extracted twice with 30 ml of ether. The organic layers were combined, washed with water, and dried over anhydrous magnesium sulfate (MgSO 4 ). The solvent was evaporated to give 2.36 g (73%) of an oily product which was crystallized in a refrigerator and recrystallized in ethanol to give 1.43 g (44%) of white needles of 1,4-bis (3,4-methylenedioxyphenyl). -2,3-dimethyl-2-butene isomer ((E) -5aa) was obtained (1.43 g, 44%), and then the mother liquor was eluted with methylene chloride (CH 2 Cl 2 ) to give silica gel chromatography. The method was carried out to obtain butenes (Z) -5ab (0.89 g, 27% yield ) in the form of an oil having the following physical properties, respectively.

1-1. 1,4-1-1. 1,4- 비스Vis (3,4-(3,4- 메틸렌디옥시페닐Methylenedioxyphenyl )-2,3-디메틸-2-) -2,3-dimethyl-2- 부텐Butene (E) 이성체: (E)- 5aa (E) Isomers: (E) -5aa

1.43g (수율; 44%)1.43g (Yield; 44%)

융점 (mp): 118-119 ℃Melting Point (mp): 118-119 ℃

1H NMR (250 MHz, CDCl3) δ 1.69 (s, 6H, 2 x CH 3), 3.34 (s, 4H, 2 x CH 2), 5.92 (s, 4H, OCH 2O), 6.63 (d, J = 7.8 Hz, 2H), 6.64 (d, J = 1.8 Hz, 2H), 6.72 (d, J = 7.8 Hz, 2H). 1 H NMR (250 MHz, CDCl 3 ) δ 1.69 (s, 6H, 2 x C H 3 ), 3.34 (s, 4H, 2 x C H 2 ), 5.92 (s, 4H, OC H 2 O), 6.63 (d, J = 7.8 Hz, 2H), 6.64 (d, J = 1.8 Hz, 2H), 6.72 (d, J = 7.8 Hz, 2H).

13C NMR (62.5 MHz, CDCl3) δ 18.86, 40.32, 101.16, 108.49, 109.21, 121.62, 129.32, 134.97, 146.03, 148.03. 13 C NMR (62.5 MHz, CDCl 3 ) δ 18.86, 40.32, 101.16, 108.49, 109.21, 121.62, 129.32, 134.97, 146.03, 148.03.

Anal Cald. for C20H20O4: C, 74.06; H, 6.21. Found: C, 74.08; H, 6.23.Anal Cald. for C 20 H 20 O 4 : C, 74.06; H, 6.21. Found: C, 74.08; H, 6.23.

1-2. 1,4-1-2. 1,4- 비스Vis (3,4-(3,4- 메틸렌디옥시페닐Methylenedioxyphenyl )-2,3-디메틸-2-) -2,3-dimethyl-2- 부텐Butene (E) 이성체: (Z)-5ab (E) Isomers: (Z) -5ab

1H NMR (250 MHz, CDCl3) δ 1.63 (s, 6H, 2 x CH 3), 3.40 (s, 4H, 2 x CH 2), 5.90 (s, 4H, OCH 2O), 6.62-6.75 (m, 6H). 1 H NMR (250 MHz, CDCl 3 ) δ 1.63 (s, 6H, 2 x C H 3 ), 3.40 (s, 4H, 2 x C H 2 ), 5.90 (s, 4H, OC H 2 O), 6.62 -6.75 (m, 6 H).

13C NMR (62.5 MHz, CDCl3) δ 18.42, 39.65, 100.70, 107.99, 108.80, 121.22, 128.63, 134.37, 145.57, 147.55. 13 C NMR (62.5 MHz, CDCl 3 ) δ 18.42, 39.65, 100.70, 107.99, 108.80, 121.22, 128.63, 134.37, 145.57, 147.55.

Anal Cald. for C20H20O4: C, 74.06; H, 6.21. Found: C, 74.06; H, 6.24.Anal Cald. for C 20 H 20 O 4 : C, 74.06; H, 6.21. Found: C, 74.06; H, 6.24.

실시예Example 2. 1,4- 2. 1,4- 비스Vis (3,4-(3,4- 디메톡시페닐Dimethoxyphenyl )-2,3-디메틸-2-) -2,3-dimethyl-2- 부텐체Butene 이성체들((E)-5ba, (Z)-5bb)의 제조 Preparation of Isomers ((E) -5ba, (Z) -5bb)

출발물질만 달리하고 상기 실시예 1에 기재된 제조공정과 동일한 공정을 수행하여 하기 물성치를 갖는 백색 침상의 부텐체 (E) 이성체 (E)-5 ba (2단계 공정 수율; 53%) 및 오일상의 부텐체 (Z) 이성체 (Z)-5bb (2단계 공정 수율; 32%)을 각각 수득하였다.A white needle-like butene (E) isomer (E) -5 ba (two-step process yield; 53%) and an oily phase having the following physical properties were carried out except for starting materials, and were subjected to the same process as described in Example 1. Butene (Z) isomer (Z) -5bb (two step process yield; 32%) was obtained respectively.

2-1. 1,4- 2-1. 1,4- 비스Vis (3,4-(3,4- 디메톡시페닐Dimethoxyphenyl )-2,3-디메틸-2-) -2,3-dimethyl-2- 부텐Butene (E) 이성체: (E)-5 (E) Isomers: (E) -5 baba

융점(mp): 104-105 ℃.Melting point (mp): 104-105 ° C.

1H NMR (250 MHz, CDCl3) δ 1.73 (s, 6H, 2 x CH 3), 3.38 (s, 4H, 2 x CH 2), 3.80 (s, 6H, 2 x OCH 3), 3.84 (s, 6H, 2 x OCH 3), 6.68-6.78 (m, 6H) 1 H NMR (250 MHz, CDCl 3 ) δ 1.73 (s, 6H, 2 × C H 3 ), 3.38 (s, 4H, 2 × C H 2 ), 3.80 (s, 6H, 2 × OC H 3 ), 3.84 (s, 6H, 2 x OC H 3 ), 6.68-6.78 (m, 6H)

2-2. 1,4-2-2. 1,4- 비스Vis (3,4-(3,4- 디메톡시페닐Dimethoxyphenyl )-2,3-디메틸-2-) -2,3-dimethyl-2- 부텐Butene (Z) 이성체: (Z)-5bb (Z) Isomers: (Z) -5bb

1H NMR (250 MHz, CDCl3) δ 1.66 (s, 6H, 2 x CH 3), 3.46 (s, 4H, 2 x CH 2), 3.83 (s, 6H, OCH 3), 3.89 (s, 6H, OCH 3), 6.65-6.88 (m, 6H). 1 H NMR (250 MHz, CDCl 3 ) δ 1.66 (s, 6H, 2 x C H 3 ), 3.46 (s, 4H, 2 x C H 2 ), 3.83 (s, 6H, OC H 3 ), 3.89 ( s, 6H, OC H 3 ), 6.65-6.88 (m, 6H).

Anal Cald. for C22H28O4: C, 74.13; H, 7.92. Found: C, 74.16; H, 7.94. Anal Cald. for C 22 H 28 O 4 : C, 74.13; H, 7.92. Found: C, 74.16; H, 7.94.

실시예Example 3. 1-4- 3. 1-4- 비스Vis (3,4-(3,4- 메틸렌디옥시페닐Methylenedioxyphenyl )-2,3-디메틸부탄체(1,4-Bis(3,4-methylenedioxyphenyl)-2,3-dimethylbutane) 화합물 및 이성체들의 제조Preparation of 1,4-Bis (3,4-methylenedioxyphenyl) -2,3-dimethylbutane) compounds and isomers

에틸아세테이트 20ml에 상기 실시예 2의 부텐체(E)-5aa (100mg, 0.31 mmol)와 PtO2(10 mg)을 파르 수소화 반응용기(Parr hydrogenation bottle)에 넣어 만든 현탁액을 교반 하면서 수소 가스를 통과시켰으며, 대략 40psi의 압력은 유지하였다. 얻어진 혼합물은 1.5시간 동안 진탕하고 불용성 물질을 제거하기 위해 여과하였다. 유기층은 물로 씻은 후 황산 마그네슘으로 건조하였다. 흰색 결정체를 얻기 위해 메탄올(CH3OH)용매로 냉장고에서 재결정하고 용매를 증발시켜 하기 물성치를 갖는 부탄체 화합물들을 얻었다.20 ml of ethyl acetate was passed through hydrogen gas while stirring the suspension prepared by adding butene (E) -5aa (100 mg, 0.31 mmol) and PtO 2 (10 mg) in the Parr hydrogenation bottle. And a pressure of approximately 40 psi was maintained. The resulting mixture was shaken for 1.5 hours and filtered to remove insoluble matter. The organic layer was washed with water and dried over magnesium sulfate. To obtain white crystals, recrystallized in a refrigerator with methanol (CH 3 OH) solvent and the solvent was evaporated to obtain butane compounds having the following physical properties.

3-1. 메소-1,4-3-1. Meso-1,4- 비스Vis (3,4-(3,4- 메틸렌디옥시페닐Methylenedioxyphenyl )-2,3-디메틸부탄 (1da)) -2,3-dimethylbutane (1da)

90mg (수율; 90%)90 mg (yield; 90%)

연노란색 오일(pale yellow oil)Pale yellow oil

융점(mp): 48-49℃ (문헌치; 48-50℃)Melting point (mp): 48-49 ° C (literature; 48-50 ° C)

1H NMR과 13C NMR 결과는 천연물질의 시료의 데이터와 동일함. 1 H NMR and 13 C NMR results are the same as the data for the natural sample.

3-2. (3-2. ( 라세믹Racemic )-1,4-) -1,4- 비스Vis (3,4-(3,4- 메틸렌디옥시페닐Methylenedioxyphenyl )-2,3-디메틸부탄 (1db)) -2,3-dimethylbutane (1db)

백색 침상; 융점 : 48-49℃ (문헌치; 48-50℃)White couch; Melting Point: 48-49 ° C (literature; 48-50 ° C)

1H NMR과 13C NMR 결과는 천연물질의 시료의 데이터와 동일함. 1 H NMR and 13 C NMR results are the same as the data for the natural sample.

3-3. (메소)-1,4-3-3. (Metho) -1,4- 비스Vis (3,4-(3,4- 디메톡시페닐Dimethoxyphenyl )-2,3-디메틸부탄 (1) -2,3-dimethylbutane (1 eaea ))

백색 침상; 융점 : 101-102℃ (문헌치; 100-101℃)White couch; Melting Point: 101-102 ° C (Literature Value; 100-101 ° C)

1H NMR과 13C NMR 결과는 이전 데이타와 동일함. 1 H NMR and 13 C NMR results are the same as in the previous data.

3-4. (3-4. ( 라세믹Racemic )-1,4-) -1,4- 비스Vis (3,4-(3,4- 디메톡시페닐Dimethoxyphenyl )-2,3-디메틸부탄 (1) -2,3-dimethylbutane (1 ebeb ))

백색 침상; 융점 : 70-71℃ (문헌치; 70.4-71.2℃)White couch; Melting Point: 70-71 ° C (Literature Value; 70.4-71.2 ° C)

1H NMR과 13C NMR 결과는 이전 기록과 동일함(무색 프리즘상). 1 H NMR and 13 C NMR results are the same as in the previous recording (colorless prism).

3-5. (3-5. ( 트레오Treo )-1-(3,4-) -1- (3,4- 메틸렌디옥시페닐Methylenedioxyphenyl )-4-(3,4-) -4- (3,4- 디메톡시페닐Dimethoxyphenyl )-2,3-디메틸부탄(1fa)) -2,3-dimethylbutane (1fa)

백색 침상; 융점 62-63℃White couch; Melting point 62-63 ℃

1H NMR (250 MHz, CDCl3) δ .79 (d, J = 6.0 Hz, 3H, CHCH 3), 0.81 (d, J = 7.0 Hz, 3H, CHCH 3), 1.75 (m, 2H), 2.51 (AB quartet, 4H, benzylic H), 3.83 (s, 3H, OCH 3), 3.85 (s, 3H, OCH 3), 5.90 (s, 2H, O-CH 2-O), 6.54-6.82 (m, 6H). 1 H NMR (250 MHz, CDCl 3 ) δ .79 (d, J = 6.0 Hz, 3H, CHC H 3 ), 0.81 (d, J = 7.0 Hz, 3H, CHC H 3 ), 1.75 (m, 2H) , 2.51 (AB quartet, 4H, benzylic H), 3.83 (s, 3H, OC H 3 ), 3.85 (s, 3H, OC H 3 ), 5.90 (s, 2H, OC H 2 -O), 6.54-6.82 (m, 6 H).

Anal Cald. for C21H26O4: C, 73.66; H, 7.65. Found: C, 73.72; H, 7.64.Anal Cald. for C 21 H 26 O 4 : C, 73.66; H, 7.65. Found: C, 73.72; H, 7.64.

3-6. (3-6. ( 에리스로Erislow )-1-(3,4-) -1- (3,4- 메틸렌디옥시페닐Methylenedioxyphenyl )-4-(3,4-) -4- (3,4- 디메톡시페닐Dimethoxyphenyl )-2,3-디메틸부탄(1) -2,3-dimethylbutane (1) fbfb ))

반고체상.Semisolid.

1H NMR (250 MHz, CDCl3) δ 0.79 (d, J = 6.0 Hz, 3H, CHCH 3), 0.81 (d, J = 7.0 Hz, 3H, CHCH 3), 1.75 (m, 2H), 2.49 (AB quartet, 4H, benzylic H), 3.82 (s, 3H, OCH 3), 3.83 (s, 3H, OCH 3), 5.90 (s, 2H, O-CH 2-O), 6.54-6.82 (m, 6H). 1 H NMR (250 MHz, CDCl 3 ) δ 0.79 (d, J = 6.0 Hz, 3H, CH CH 3 ), 0.81 (d, J = 7.0 Hz, 3H, CHC H 3 ), 1.75 (m, 2H), 2.49 (AB quartet, 4H, benzylic H), 3.82 (s, 3H, OC H 3 ), 3.83 (s, 3H, OC H 3 ), 5.90 (s, 2H, OC H 2 -O), 6.54-6.82 ( m, 6H).

Anal Cald. for C21H26O4: C, 73.66; H, 7.65. Found: C, 73.76; H, 7.66.Anal Cald. for C 21 H 26 O 4 : C, 73.66; H, 7.65. Found: C, 73.76; H, 7.66.

실시예Example 4. 1-(3,4- 4. 1- (3,4- 디메톡시페닐Dimethoxyphenyl )-4-(3-) -4- (3- 메톡시Methoxy -4--4- 히드록시페닐Hydroxyphenyl )-2,3-디메틸부탄체(1-(3,4-Dimethoxyphenyl)-4-(3-methoxy-4-hydroxyphenyl)- 2,3-dimethylbutane, 일명 ) -2,3-dimethylbutane (1- (3,4-Dimethoxyphenyl) -4- (3-methoxy-4-hydroxyphenyl) -2,3-dimethylbutane, aka MesoMeso -- monomethyldihydroguaiareticmonomethyldihydroguaiaretic acid) 화합물 (1ca) 및 이성체들의 제조 acid) Preparation of Compound (1ca) and Isomers

상기 단계에서 얻은 화합물 1fa(1.0 g, 0.32 mmol), 파라티오크레솔 (2.0 g)과 NaH (1.0 g)을 DMF (30 mL)에 가하여 생성된 현탁액을 1시간 환류시킨다. 반응액을 상온으로 냉각시키고 물(100 ml)을 가해 희석한 다음 염산으로 중화하고 벤젠 으로 추출한다 (100 ml x 3회). 유기층을 합한 다음 물로 세척하고 황산나트륨(Na2SO4)으로 건조한 후 농축하여 오일(1.1 g, 94%)을 얻는다. 얻은 오일 (1.1 g, 0.30 mmol), 황산 메틸 (2 mL)과 무수 탄산칼륨(K2CO3, 1.0 g)을 아세톤 (50 mL)에 가하여 얻은 현탁액을 6시간 환류시킨다. 반응액을 여과한 다음 농축하여 얻은 조생성물을 1 N 메탄올-염산 (25 mL)을 가하여 0.5시간 환류시킨다. 반응액에 물(30 ml)을 가하여 희석한 다음 벤젠 (30 ml x 3회)으로 추출한다. 벤젠층을 합하고 물로 세척, 건조한 다음 농축하여 얻은 오일상의 생성물을 실리카겔(25g)로 컬럼 크로마토그래피(용출액 헥산 : 벤젠 = 1 : 3)로 정제하여 오일상의 목적 생성물 (1ca)을 0.62 g (65%) 얻었다. Compound 1fa (1.0 g, 0.32 mmol), parathiocresol (2.0 g) and NaH (1.0 g) obtained in the above step were added to DMF (30 mL), and the resulting suspension was refluxed for 1 hour. The reaction solution was cooled to room temperature, diluted with addition of water (100 ml), neutralized with hydrochloric acid and extracted with benzene (100 ml x 3 times). The combined organic layers were washed with water, dried over sodium sulfate (Na 2 SO 4 ) and concentrated to give an oil (1.1 g, 94%). The resulting oil (1.1 g, 0.30 mmol), methyl sulfate (2 mL) and anhydrous potassium carbonate (K 2 CO 3 , 1.0 g) were added to acetone (50 mL) and the resulting suspension was refluxed for 6 hours. The reaction solution was filtered, and then the crude product obtained by concentration was added with 1 N methanolic hydrochloric acid (25 mL) and refluxed for 0.5 hour. Water (30 ml) was added to the reaction mixture, diluted with water, and extracted with benzene (30 ml x 3 times). The benzene layers were combined, washed with water, dried and concentrated. The oily product was purified by column chromatography (eluent hexane: benzene = 1: 3) with silica gel (25 g ) to give 0.62 g (65% ) of the desired product (1ca) as oil. )

수율: 65%Yield: 65%

1H NMR δ 0.80 (d, J = 6 Hz, 6H), 1.75 (m, 4H), 2.50 (m, 4H), 3.80 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 5.55 (s, D2O-exchangeable, OH), 5.88 (s, 2H), 6.45-6.90 (m, 6H). 1 H NMR δ 0.80 (d, J = 6 Hz, 6H), 1.75 (m, 4H), 2.50 (m, 4H), 3.80 (s, 3H, OCH 3 ), 3.83 (s, 3H, OCH 3 ), 3.85 (s, 3H, OCH 3 ), 5.55 (s, D 2 O-exchangeable, OH), 5.88 (s, 2H), 6.45-6.90 (m, 6H).

실시예Example 5. (메소)- 5. (Meso) 노르디하이드로갈리아레틱산(NDGA, 1aa)의Of nordihydrogalliatic acid (NDGA, 1aa) 제조 Produce

상기 단계에서 얻은 화합물(1 ea )(358 mg, 1.0 mmol)과 메틸렌클로라이드를 용매로 한 브롬화 붕소(BBr3, 10ml, 1.0M 용액)의 혼합용액을 건조 메틸렌클로라이드 10ml에 용해하고 Ar 기류하에서 -78 ℃에서 1.5시간 동안 교반한 다음 반응 혼 합물이 상온에 도달한 다음 통상적인 방법으로 조작하여 미황색 고체를 얻었다. 메탄올을 전개용매로 실리카겔 크로마토그래피법을 수행하고 용출액(eluent)으로부터 재결정 후에 크림색 침상결정의 목적하는 (메소)-노르디하이드로갈리아레틱산(NDGA, 1aa)(227mg)을 수득하였다. A mixed solution of the compound (1 ea ) (358 mg, 1.0 mmol) obtained in the above step and boron bromide (BBr 3 , 10 ml, 1.0 M solution) using methylene chloride as a solvent was dissolved in 10 ml of dry methylene chloride and under Ar stream. After stirring at 78 ° C. for 1.5 hours, the reaction mixture reached room temperature and then operated in a conventional manner to obtain a pale yellow solid. Methanol was subjected to silica gel chromatography using a developing solvent, and recrystallized from an eluent to obtain the desired (meth) -nordihydrogalaliaretic acid (NDGA, 1aa) (227 mg) of a cream acicular crystal.

융점 : 185-186℃ (문헌치; 184-185℃)Melting Point: 185-186 ° C (Literature Value; 184-185 ° C)

1H NMR (250 MHz, CD3OD) δ 0.79 (d, J = 6.0 Hz, 6H, CHCH 3), 1.66 (q, J = 7.0 Hz, 2H, CHCH3), 2.12 (dd, J = 13.0, 9.0 Hz, 2H, benzylic H), 2.61 (dd, J = 13.0, 6.0 Hz, 2H, benzylic H), 4.98 (br. s, 4H, OH), 6.37 (dd, J = 7.8, 1.2 Hz, 2H), 6.62 (d, J = 1.2 Hz, 2H), 6.73 (d, J = 7.8 Hz, 2H). 1 H NMR (250 MHz, CD 3 OD) δ 0.79 (d, J = 6.0 Hz, 6H, CHC H 3 ), 1.66 (q, J = 7.0 Hz, 2H, C H CH 3 ), 2.12 (dd, J = 13.0, 9.0 Hz, 2H, benzylic H), 2.61 (dd, J = 13.0, 6.0 Hz, 2H, benzylic H), 4.98 (br. S, 4H, OH), 6.37 (dd, J = 7.8, 1.2 Hz , 2H), 6.62 (d, J = 1.2 Hz, 2H), 6.73 (d, J = 7.8 Hz, 2H).

본 발명의 항산화제로 유용한 NDGA 및 그 유도체 화합물을 제조하는 신규 제조방법은 종래기술상의 문제점인 고비용 및 소량 생산 등의 단점을 개선하여 목적물질을 고수율 및 저비용으로 대량 생산이 가능하도록 하였다. 또한 종전의 방법으로는 불가능하였던 비대칭 NDGA의 합성이 가능하게 하여 비대칭 NDGA를 제조할 수 있도록 하였다.The novel production method for preparing NDGA and its derivative compounds useful as the antioxidant of the present invention improves the disadvantages of high cost and small amount production, which are problems of the prior art, so that mass production of the target material is possible at high yield and low cost. In addition, it was possible to prepare asymmetric NDGA by synthesizing asymmetric NDGA, which was not possible with the previous method.

Claims (4)

하기 브롬체 화합물(2)로부터 제조한 그리그나드 시약과 케톤체 (3) 와 반응시켜 알콜체(4)를 제조하는 제 1단계; 상기 알콜체 (4)를 탈수제로 탈수반응하여 부텐체의 (Z)이성체 (5 Z) 및 (E)이성체 (5 E)를 각각 얻는 제 2단계; 상기 2단계의 각각의 부텐체의 (Z) 및 (E) 이성체들을 촉매 존재하에 수소화 반응시켜 부탄체의 메소 이성체 (6- meso ) 및 라세믹 이성체((±)-6)를 각각 얻는 제 3단계; 상기 단계의 부탄체의 메소 및 라세믹 이성체들을 탈메틸화 반응을 시키는 제4단계 공정을 포함하는 일반식 (1)의 NDGA 유도체를 고수율로 수득하는 신규 제조방법:A first step of reacting a Grignard reagent prepared from a bromine compound (2) with a ketone body (3) to produce an alcohol body (4) ; A second step of dehydrating the alcohol (4) with a dehydrating agent to obtain (Z) isomers (5 Z) and (E) isomers (5 E) of the butenes, respectively; A third step in which the (Z) and (E) isomers of the respective butenes of the second step are hydrogenated in the presence of a catalyst to obtain meso isomers (6- meso ) and racemic isomers ((±) -6) of the butanes, respectively; step; Novel preparation method for obtaining NDGA derivative of general formula (1) comprising a fourth step of demethylating the meso and racemic isomers of butane in the above step:
Figure 112006004305024-PAT00018
Figure 112006004305024-PAT00019
Figure 112006004305024-PAT00018
Figure 112006004305024-PAT00019
Figure 112006004305024-PAT00020
Figure 112006004305024-PAT00020
Figure 112006004305024-PAT00021
Figure 112006004305024-PAT00021
Figure 112006004305024-PAT00022
Figure 112006004305024-PAT00022
Figure 112006004305024-PAT00023
Figure 112006004305024-PAT00023
Figure 112006004305024-PAT00024
Figure 112006004305024-PAT00024
상기 식에서 X는 메틸렌기 또는 개환시 수소 원자 또는 메틸기, 에틸기 등의 저급 알킬기이다. In the above formula, X is a lower alkyl group such as a methylene group or a ring-opened hydrogen atom or a methyl group or an ethyl group.
Figure 112006004305024-PAT00025
Figure 112006004305024-PAT00025
상기 식에서 R1 내지 R4 기는 각각 독립적으로 수소 원자, 또는 메틸기, 에틸기 등의 저급 알킬기이며 서로 같거나 다를 수 있다. In the above formula, R 1 to R 4 groups are each independently a hydrogen atom or a lower alkyl group such as a methyl group or an ethyl group and may be the same as or different from each other.
제 1항에 있어서, 상기 제 2단계의 탈수제는 황산(H2SO4)을 사용함을 특징으로 하는 제조방법.The method of claim 1, wherein the dehydrating agent of the second step uses sulfuric acid (H 2 SO 4 ). 제 1항에 있어서, 상기 제 3단계의 수소화 반응 단계에는 촉매로서 PtO2를 사용함을 특징으로 하는 제조방법.The method according to claim 1, wherein the third hydrogenation reaction step uses PtO 2 as a catalyst. 제 1항에 있어서, 상기 제 4단계에서 탈메틸화 반응에 사용하는 탈메틸화 시약으로는 삼불화붕소를 사용함을 특징으로 하는 제조방법.The method according to claim 1, wherein boron trifluoride is used as the demethylation reagent used in the demethylation reaction in the fourth step.
KR1020060006119A 2006-01-20 2006-01-20 A preparation method of nordihydroguaiaretic acid and its analogues KR100783626B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020060006119A KR100783626B1 (en) 2006-01-20 2006-01-20 A preparation method of nordihydroguaiaretic acid and its analogues

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020060006119A KR100783626B1 (en) 2006-01-20 2006-01-20 A preparation method of nordihydroguaiaretic acid and its analogues

Publications (2)

Publication Number Publication Date
KR20070076800A true KR20070076800A (en) 2007-07-25
KR100783626B1 KR100783626B1 (en) 2007-12-11

Family

ID=38501562

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020060006119A KR100783626B1 (en) 2006-01-20 2006-01-20 A preparation method of nordihydroguaiaretic acid and its analogues

Country Status (1)

Country Link
KR (1) KR100783626B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102117651B1 (en) 2018-04-27 2020-06-02 대구가톨릭대학교산학협력단 Oriental medicine composition for anti-oxidation, anti-wrinkle or anti-inflammation and cosmetic composition comprising the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2644822A (en) 1949-08-26 1953-07-07 Sulphite Products Corp 2, 3-bis-(oxybenzyl)-butane derivatives

Also Published As

Publication number Publication date
KR100783626B1 (en) 2007-12-11

Similar Documents

Publication Publication Date Title
EP1860103A1 (en) Anticancer compound, intermediate therefor, and processes for producing these
US5780675A (en) Deoxygossylic compounds
KR100783626B1 (en) A preparation method of nordihydroguaiaretic acid and its analogues
Khrimian et al. Absolute configurations of stink bug-and plant-produced sesquipiperitols via synthesis of all stereoisomers
FR2539624A1 (en) CYCLOHEXANOL DERIVATIVES AND PERFUME COMPOSITIONS CONTAINING SAME
CA1250313A (en) METHOD OF PREPARING .alpha.-CHLORINATED UNSATURATED COMPOUNDS WITH TWO ELECTROATTRATIVE GROUPS IN POSITION .beta.
Son et al. A simple synthesis of nordihydroguaiaretic acid and its analogues
US5990322A (en) Alpha-tocopherol cyclopropylates, the new vitamin E derivatives and method for producing the same
Naik et al. 1, 5-diphenylpenta-1, 4 dien-3-ones: A novel class of free radical scavengers
Johnson et al. The chemistry of hindered systems. II. The acyloin reaction-an approach to regiospecifically hydroxylated tetramethylazacycloheptane systems
KR100270410B1 (en) Novel 1,3-diphenylpropane derivative having inhibitive activity against tyrosinase and process for preparation thereof
JP2718645B2 (en) Benzoheterocyclic compound, method for producing the same and composition containing the same
US4764641A (en) Process for preparing optically active carbonyl compounds
US5306844A (en) Tartaric acid amide derivative and method of producing the same
US4338255A (en) Modified lithium aluminum hydrides
Reinaud et al. Synthesis of new 3-(-2-alkenyl)-2-hydroxy-5-methoxy-p-benzoquinones via Claisen rearrangement of original 5-methoxy-4-(2-propenyloxy)-o-benzoquinones
SATO et al. Psychotropic Agents. IV. Syntheses of β-Phenyl-γ-butyrolactone Derivatives
US5936120A (en) Deoxygossylic compounds
WO2013008175A1 (en) Method for producing trans-resveratrol and the analogs thereof
KR100932071B1 (en) Method for preparing benzal acetophenone derivative
Venkateswarlu et al. Synthesis and Antioxidant Activity of 4-[2-(3, 5-Dimethoxyphenyl) ethenyl]-1, 2-benzenediol, a Metabolite of Sphaerophysa salsula
KATAOKA et al. Synthesis, Stereochemistry and Reactions of Selenoxanthen-10-io (alkoxalyl alkoxycarbonyl) methanides and Related Compounds
JPS63501564A (en) Racemic nordihydroguaiaretic acid and intermediates
Mirek et al. Spiroferrocenophanes: I. 3-Spiro [5] ferrocenophane-1, 5-diones from the direct condensation of diacetylferrocene with cycloalkanones
Dreiding et al. The Structure of the Solid Product from the Condensation of Methyl γ-Bromocrotonate with Sodium Methoxide1

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121119

Year of fee payment: 6

FPAY Annual fee payment

Payment date: 20131011

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee